Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy
Anne E Schuind, Kanduri Ananth Balaji, Anna Du, Yuan Yuan, Peter Dull · 2024
Read Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policy by Anne E Schuind, Kanduri Ananth Balaji, Anna Du, Yuan Yuan, Peter Dull (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11555274.txt.
Description
Human papillomavirus (HPV) prophylactic vaccines were first licensed in 2006 with the primary goal of preventing HPV-related cancers, with cervical cancer accounting for the highest morbidity and mortality globally. Six HPV vaccines have been licensed; 4 of these have been prequalified by the World Health Organization, and additional products are in the pipeline.
Catalog record
| CREATOR | Anne E Schuind, Kanduri Ananth Balaji, Anna Du, Yuan Yuan, Peter Dull |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |